Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMD plus chemotherapy and tislelizumab as neoadjuvant treatment for operable NSCLC
ChiCTR2500102195Phase 2Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- May 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, pemetrexed, paclitaxel, cisplatin and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Army Medical Center of PLA. Primary endpoint: major pathologic response. Planned start May 2025; status: not yet recruiting.
02
Drugs
tislelizumabpemetrexedpaclitaxelcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102195.